title: Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects.
abstract: BACKGROUND
  The relationship of monocyte/macrophage activation to insulin resistance in obesity is unknown.
  
  
  OBJECTIVE
  To investigate a marker of macrophage activation, soluble CD163 (sCD163), in relationship to insulin resistance and metabolic parameters in obese and normal-weight subjects.
  
  
  METHODS
  Ninety-five healthy subjects (65 obese and 30 normal-weight) were studied. Plasma concentrations of sCD163 were assessed, as well as markers of glucose homeostasis, anthropometrics, cytokines and adipokines. The relationships between sCD163 and these parameters were investigated, and multiple regression modelling assessing the contribution of sCD163 to insulin resistance (HOMA-IR) was performed.
  
  
  RESULTS
  Soluble CD163 was significantly increased in obese subjects compared with normal-weight controls [974 (657, 1272) ng/ml vs 599 (423, 892) ng/ml, median (IQR); P < 0·0001]. sCD163 was strongly associated with HOMA-IR (Spearman's ρ = 0·37, P = 0·0003) and other metabolic parameters. In multiple regression modelling for log HOMA-IR, sCD163 remained significantly associated (P = 0·005) controlling for known mediators of insulin resistance including age, gender, visceral adiposity and inflammatory markers (model R(2) = 0·54, P < 0·0001). Additional nested multiple regression models for log HOMA-IR showed that sCD163 added more than other adipokines and inflammatory markers to the prediction of HOMA-IR.
  
  
  CONCLUSIONS
  Monocyte/macrophage activation, as reflected by sCD163 levels, is strongly associated with HOMA-IR in normal-weight and obese subjects after controlling for known mediators of insulin resistance. Moreover, sCD163 adds to standard risk markers for predicting insulin resistance. These data suggest that monocyte/macrophage activation may be an important determinant of insulin resistance in obesity.
authors.affiliation: Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
authors.forename: Markella V
authors.initials: MV
authors.lastname: Zanni
authors.forename: Tricia H
authors.initials: TH
authors.lastname: Burdo
authors.forename: Hideo
authors.initials: H
authors.lastname: Makimura
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Williams
authors.forename: Steven K
authors.initials: SK
authors.lastname: Grinspoon
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000276:immunology; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007333:Insulin Resistance / Q000276:immunology*; D008262:Macrophage Activation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000276:immunology* / Q000473:pathology; D011956:Receptors, Cell Surface / Q000097:blood*; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; D000098902:CD163 Antigen; D011956:Receptors, Cell Surface
references.citation: Metabolism. 1999 Oct;48(10):1332-5
references.pmid: 10535400
references.citation: Clin Chem. 2011 Feb;57(2):291-7
references.pmid: 21106861
references.citation: Blood. 2002 Jan 1;99(1):378-80
references.pmid: 11756196
references.citation: J Clin Invest. 2008 Sep;118(9):2992-3002
references.pmid: 18769626
references.citation: Eur J Haematol. 2005 Jan;74(1):6-10
references.pmid: 15613100
references.citation: J Clin Endocrinol Metab. 2009 Dec;94(12):5131-8
references.pmid: 19837914
references.citation: Biochem Biophys Res Commun. 1999 Mar 5;256(1):110-3
references.pmid: 10066432
references.citation: Diabetes Care. 1994 Sep;17(9):961-9
references.pmid: 7988316
references.citation: Int J Obes (Lond). 2009 Nov;33(11):1257-64
references.pmid: 19687791
references.citation: Ann Intern Med. 1995 Apr 1;122(7):481-6
references.pmid: 7872581
references.citation: Free Radic Biol Med. 2005 Jul 1;39(1):98-107
references.pmid: 15925282
references.citation: Int J Obes (Lond). 2007 Sep;31(9):1420-8
references.pmid: 17593905
references.citation: JAMA. 2010 Jan 20;303(3):235-41
references.pmid: 20071471
references.citation: Eur J Clin Invest. 2009 Aug;39(8):671-9
references.pmid: 19490068
references.citation: Mol Immunol. 2010 Apr;47(7-8):1650-60
references.pmid: 20299103
references.citation: J Clin Endocrinol Metab. 2008 Nov;93(11):4254-60
references.pmid: 18765508
references.citation: J Leukoc Biol. 2002 Oct;72(4):711-7
references.pmid: 12377940
references.citation: J Leukoc Biol. 2010 Dec;88(6):1201-5
references.pmid: 20807704
references.citation: Circulation. 2000 Jul 4;102(1):42-7
references.pmid: 10880413
references.citation: J Clin Invest. 1995 May;95(5):2409-15
references.pmid: 7738205
references.citation: N Engl J Med. 1998 Jul 23;339(4):229-34
references.pmid: 9673301
references.citation: J Infect Dis. 2011 Jul 1;204(1):154-63
references.pmid: 21628670
references.citation: J Leukoc Biol. 2006 Jul;80(1):26-35
references.pmid: 16799153
references.citation: Atherosclerosis. 2006 Feb;184(2):342-7
references.pmid: 15979079
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):504-10
references.pmid: 11158000
references.citation: Nature. 2001 Jan 11;409(6817):198-201
references.pmid: 11196644
references.citation: J Clin Endocrinol Metab. 1998 Aug;83(8):2907-10
references.pmid: 9709967
references.citation: Circulation. 2002 Nov 19;106(21):2659-65
references.pmid: 12438290